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Abstract 
This paper describes the synthesis and biological evaluation of macrolactones 
containing  a  thienyl substituent  as simple analogues of epothilones. The 
compounds were prepared in a brief and efficient manner from thiophene-2-
carbaldehyde using a ring-closing metathesis with Grubbs I or Grubbs II catalyst 
as the key step. The target lactones showed only insignificant cytotoxicity, while 
an intermediate simple thienyl carbinol showed very promising cytotoxicity.  
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Introduction 
The macrolactone scaffold is found in numerous natural products [1, 2] which show a wide 
range of pharmacological properties including antimicrobial and cytotoxic activities. 
Prominent examples are the 14-membered lactone antibiotics  erythromycin  and 
telithromycin, as well as their 15-membered, semisynthetic derivative azithromycin [3], the 
cytotoxic  salicylihalamides  (12-membered lactones) [4, 5], the 18-membered cytotoxic 
antibiotic FD-891 [6] and the epothilones, cytotoxic 16-membered lactones which inhibit 
microtubule function [7]. Extensive investigations on total syntheses [8] and analysis of 
structure-activity relationships of epothilones have been performed in the past, and a 
number of substances from this class have entered clinical studies [9]. Sagopilone, a new 
clinical candidate from the epothilone family [10], demonstrates that the rather complex 30  J. Krauss et al.:   
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methylthiazolylpropenyl residue of native epothilones can be replaced by a simple 
heteroaromatic residue, in this case a benzothiazole. 
This prompted us to investigate a new type of 16-membered lactones bearing a sulphur-
containing hetarene, namely a thiophene ring [11], next to the lactone oxygen in analogy to 
new synthetic epothilones. The target compounds were to be prepared using the ring-
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Fig. 1.   Structures of epothilone B (I) and sagopilone (II) 
Results and Discussion 
Thiophene-2-carbaldehyde (1) was reacted in a Grignard reaction with  pent-4-enyl-
magnesium bromide to give alcohol 2, following a methodology we had worked out earlier 
for furan derivatives [14, 15].  Secondary alcohol 2  was esterified with undec-10-enoyl 
chloride to give the ester 3. From this intermediate containing two terminal vinyl groups the 
macrolactone 4 was prepared in a ring-closing metathesis under high dilution conditions 
using either Grubbs I catalyst, benzylidene(dichloro)bis(tricyclohexylphosphane)ruthenium, 
or Grubbs II catalyst, benzylidene[1,3-bis(2,4,6-trimethylphenyl)  2-imidazolidinylidene]-
dichloro(tricyclohexylphosphane)ruthenium.  When using Grubbs II catalyst,  the reaction 
proceeded faster than with Grubbs I catalyst (6 h vs. 24 h), for comparable observations 
see ref. [12, 16, 17].  
Both 1
st and 2
nd generation Grubbs catalysts gave the expected 16-membered lactone 4 
as E/Z mixtures (Grubbs I catalyst: E/Z = 66:34; Grubbs II catalyst: E/Z = 77:23). The E/Z 
isomers could not be separated by flash column chromatography. The ratio of the isomers 
was determined by GLC-MS and NMR spectroscopy. The predominating E-isomer was 
identified by the vicinal coupling constant of both olefinic protons of 
3J = 15.3 Hz. Since 
both olefinic hydrogens showed the same chemical shift, the signal and the coupling 
constants were verified by computer-aided techniques (NutsPro – NMR Utility Transform 
Software – Professional, 2D Professional Version – 20020107). The simulated 
1H-NMR 
signal and the simulated coupling constants for the olefinic protons of the E-isomer were in 
full accordance to the measured signal and coupling constants (Fig. 2).    Synthesis and Cytotoxic Evaluation of New Thienylmacrolactones  31 
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Fig. 2.  
1H-NMR resonances of the olefinic protons of the E-configurated product 4 
(left), and simulated 
1H-NMR resonances for the E-isomer with 
3J = 15.3 Hz for 
the coupling of the olefinic protons and 
3J = 7.0 Hz for the coupling of the 
olefinic protons with the neighboring methylene protons.  
Since in preliminary screenings lactone 4 showed negligible cytotoxicity, we intended to 
introduce hydroxy groups into the ring system to enhance structural similarity to the 
epothilones. The olefinic double bond of the E/Z mixture 4 could be dihydroxylated using a 
Sharpless  dihydroxylation  with  β-AD-mix
®  (OsO4, K3Fe(CN)6, K2CO3, (DHQD)2-PHAL) 




























Sch. 1.  a: THF. b: toluene, EDMA. c: toluene, Grubbs catalyst (1
st or 2
nd generation), 
high dilution technique. d: tert.-butanol / H2O, β-AD mix
®.  32  J. Krauss et al.:   
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The resulting lactones as well as the precursors 2 and 3 were tested in an agar diffusion 
assay against several bacteria and fungi. The compounds  showed no significant 
antimicrobial activities compared to tetracycline or clotrimazol. 
The cytotoxicity was determined in a MTT assay on HL-60 cells (human leukaemia cell 
line) using the method of Mosmann  [19].  The macrolactones 4  and  5  exhibited  only 
extremely  weak cytotoxic activity.  Only the secondary alcohol  2 showed  high cytotoxic 
activity in the low µM range (Tab. 1). Compound 5 was also tested in the NCI single high 
dose cell panel assays  on 59 cell lines, but showed no remarkable selectivity or 
cytotoxicity in this assay.  
Tab. 1.   Cytotoxicity against HL 60 cells. 




2  6 (1.1)  3.2 
3  > 100  7.2 
4  290 (92.8)  6.1 
5  120 (42.5)  4.2 
cisplatin  5 (1.5)   
 
Conclusion 
In conclusion, we worked out a short and efficient synthesis of novel thienyl macrolactones 
related to the epothilones.  The resulting lactones  4  and  5  did not show  significant 
anticancer or antimicrobial activities.  
We supposed that a reason for the negligible cytotoxic activity of lactone 4 might be its 
very high lipophilicity, as shown by the calculated log P value (Tab. 1). The log P of 7.2 is 
much higher than the log P limits defined by Lipinski (−0.4 to +5.6) [20] for drug likeness. 
In fact, the diol 5 (calculated log P = 4.2) showed increased cytotoxicity compared to 4, but 
still is far away from being an interesting lead. To our great surprise, the secondary thienyl 
carbinol 2 showed very interesting cytotoxic activity (IC50 = 6 µM). This reminds us of an 
accidental observation in previous work [12] where a side-product containing a furyl 
carbinol showed comparable cytotoxicity.  
Work is in progress to gain deeper insight into structure-activity relationships of the 
interesting class of heteroaryl carbinols and to identify their molecular mode of action. 
Experimental 
General 
Elemental analysis: Heraeus CHN–Rapid; IR-Spectra: Perkin-Elmer FT-IR Paragon 1000; 
MS: Hewlett Packard MS-Engine; electron ionisation (EI) 70 eV, chemical ionisation (CI) 
with CH4 (300 eV); NMR: Jeol GSX 400 (
1H: 400 MHz, 
13C: 100 MHz); melting points: 
Büchi Melting Point B-540 (not corrected); flash column chromatography (FCC): silica gel 
60 (230–400 mesh, E. Merck, Darmstadt); GLC-MS: Shimadzu GC-17 A (carrier: He, oven   Synthesis and Cytotoxic Evaluation of New Thienylmacrolactones  33 
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temperature program: 100–280 °C, 10 °C / min, capillary column: Varian VF-5ms 30 m × 
0.25, split injector T = 250 °C, detector T = 260 °C).  
(±)-1-(Thiophen-2-yl)-hex-5-en-1-ol (2) 
To a mixture of 1.53 g (66.5 mmol) magnesium turnings and an iodine crystal in dry THF 
(25 mL) was added 6.60 g (44.3 mmol) 1-bromopent-4-ene in two portions. The mixture 
was heated until the Grignard reaction started. The suspension was heated under reflux 
for further 1 h.  
To a solution of 3.30 g (29.5 mmol) thiophene-2-carbaldehyde (1) in 15 ml dry THF the 
prepared solution of pent-4-enylmagnesium  bromide in THF was  added dropwise. The 
mixture was stirred for 4 h, than quenched with 30 mL 5 % aqueous NH4Cl solution and 
extracted with diethyl ether (3 × 30 mL). The combined organic layers were dried over 
Na2SO4 and the solvent was evaporated. The residue was purified by FCC (n-hexane/ethyl 
acetate 5:1) to give 4.30 g (80%) of 2 as a colourless oil. 
1H-NMR (400 MHz, CDCl3): δ 
(ppm) = 1.42 (m, 1H, 3-H), 1.55 (m, 1H, 3-H), 1.85 (m, 2H, 2-H), 2.09 (m, 2H, 4-H), 2.16 
(s, 1H, OH), 4.90 (t, J = 6.5 Hz, 1H, 1-H), 4.95 (m, 1H, 6-H), 5.01 (m, 1H, 6-H), 5.79 (m, 
1H, 5-H), 6.95 (m, 2H, 2`-H, 3`-H), 7.23 (m, 1H, 4´-H). 
13C-NMR (400 MHz, CDCl3): δ 
(ppm) = 25.0 (C-3), 33.4 (C-4), 38.7 (C-2), 70.2 (C-1), 114.8 (C-6), 123.7 (C-5`), 124.5 (C-
3´), 126.6 (C-4´), 138.4 (C-5), 148.8 (C-2`). EI-MS m/z (rel. int.): 182 (M
+, 100), 164 (M
+-
18, 30), 97 (75). IR (NaCl, film): ν [cm
−1] = 3379, 3074, 2936, 1860, 1640, 1439, 1414, 
1066, 1029, 995, 912, 852, 830, 699. Elemental analysis: C10H14OS (182.29). Calcd.: C: 
65.89. H: 7.74. S: 17.59. Found: C: 65.71. H: 7.91. S: 17.17. 
(±)-1-(Thiophen-2-yl)hex-5-en-1-yl undec-10-enoate (3) 
1.60 g (8.80 mmol) of 2 were dissolved in 30 mL dry toluene, 2.10 g (10.6 mmol) undec-
10-enoyl chloride and 5 mL N-ethyl-N,N-dimethylamine (EDMA) were added. The mixture 
was stirred for 5 h and then the solvent was evaporated. The residue was dispersed in 
20 mL water and extracted with diethyl ether (3 × 30 mL). The combined organic layers 
were dried over Na2SO4 and the solvent was evaporated. The residue was purified by FCC 
(n-hexane/ethyl acetate 10:1 to 5:1) to give 1.85 g (60%) of 3 as a colourless oil. 
1H-NMR 
(400 MHz, CDCl3): δ (ppm) = 1.26 (m, 8H, 4 CH2), 1.36 (m, 4H, 2 CH2), 1.58 (m, 2H, CH2), 
1.89 (m, 1H, CH2), 2.03 (m, 3H, CH2, CH2), 2.09 (m, 2H, CH2), 2.30 (t, J = 8.0 Hz, 2H, 
CH2), 4.96 (m, 4H, 2 =CH2), 5.79 (m, 2H, 2 -CH=), 6.04 (t, J = 7.4 Hz, 1H, CH), 6.95 (dd, J 
= 4.9 Hz, J = 3.4 Hz, 1 H, aromat. CH), 7.03 (d, J = 3.4 Hz, 1H, aromat. CH), 7.25 (dd, J = 
4.9 Hz, J = 1.1 Hz, 1H, aromat. CH). 
13C-NMR (400 MHz, CDCl3): δ (ppm) = 24.8 (CH2), 
24.9 (CH2), 28.9 (CH2), 29.0 (CH2), 33.2 (CH2), 33.8 (CH2), 34.5 (CH2), 35.8 (CH2), 70.8 
(CH), 114.1 (=CH2), 115.0 (=CH2), 125.1 (aromat. CH-), 125.7 (aromat. CH-),  126.5 
(aromat. CH-), 138.2 (=CH-), 139.2 (=CH-), 143.7 (quart. C), 173.1 (CO). EI-MS m/z (rel. 
int.):348 (M
+, 2), 182 (100), 97 (94). Elemental analysis: C21H32O2S (348.55). Calcd.: C: 
72.37. H: 9.25. S: 9.20. Found: C: 72.99. H: 9.78. S: 8.60.  
(±)-16-(Thiophen-2-yl)-oxacyclohexadec-11-en-2-one (4) (E/Z-mixture) 
1.0 g (2.9 mmol) of 3 and 0.16 g (0.20 mmol) of Grubbs I catalyst (or 0.17 g (0.20 mmol) 
Grubbs II catalyst) were dissolved separately in 5 mL dry toluene each. Using two syringe 
pumps  these solutions were simultaneously added dropwise to 250  mL of boiling dry 
toluene over a period of 12 h for Grubbs I and of 4 h for Grubbs II catalyst. The mixture 
was heated under reflux for another 12 hours under a N2-atmosphere for Grubbs I and 2 h 34  J. Krauss et al.:   
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for Grubbs II catalyst. Then the solvent was evaporated and the residue was purified by 
FCC (n-hexane/ ethyl acetate 9:1) to give 690 mg (74% for Grubbs I), 790 mg (86 % for 
Grubbs II) of 4 as a colourless oil. 
1H-NMR (400 MHz, D6-benzene): resonances of the 
predominating E-isomer: δ (ppm) = 1.28 (m, 10H, 5 CH2), 1.55 (m, 4H, 2 CH2), 1.94 (m, 
4H, 2 CH2), 2.25 (m, 4H, 2 CH2), 5.22 (m, 2H, 2 CH= containing a coupling constant of J = 
15.3 Hz), 6.32 (t, J = 7.8 Hz, 1H, CH), 6.90 (dd, J = 4.9 Hz, J = 3.2 Hz, 1H, aromat. CH), 
6.99 (d, J = 3.2 Hz, 1H, aromat. CH), 7.20 (m, 1H, aromat. CH). 
13C-NMR (400 MHz, D6-
benzene): resonances of the predominating E-isomer: δ (ppm) = 25.2 (CH2), 25.6 (CH2), 
26.6 (CH2), 27.4 (CH2), 28.1 (CH2), 28.2 (CH2), 28.3 (CH2), 32.0 (CH2), 32.2 (CH2), 34.9 
(CH2), 35.7 (CH2), 71.0 (CH), 125.4 (aromat. CH), 126.0 (aromat. CH), 126.5 (aromat. 
CH), 130.5 (-CH=), 132.0 (-CH=), 143.3 (quart. C), 173.1 (CO). CI-MS m/z (rel. int.): 320 
(M
+, 15), 110 (100). HR-MS:  Calcd.:  320.1810.  Found.: 320.1810. Elemental analysis: 
C19H28O2S (320.50). Calcd.: C: 71.28. H: 8.81 S: 10.00. Found: C: 71.87. H: 9.08. S: 9.90.  
(±)-11,12-Dihydroxy-16-(thiophen-2-yl)-oxacyclohexadecan-2-one (5) (mixture of 
stereoisomers) 
250 mg (0.781 mmol) of lactone 4 were dissolved in 50 mL tert.-butanol/water (1:1) and 
5.5  g  β-AD mix
®  (Aldrich)  were added. The suspension was stirred for  12 h at room 
temperature. Then it was quenched with 100 mL  5 % aqueous Na2S2O3  solution and 
extracted with diethyl ether (3 × 30 mL). The combined organic layers were dried over 
Na2SO4, the solvent was evaporated and the residue was purified by FCC (n-hexane/ethyl 
acetate 1:1) to give 210 mg (76%) of 5 as a colourless oil. 
1H-NMR (400 MHz, CDCl3): δ 
(ppm) = 1.31 (m, 14H, 7 CH2), 1.63 (m, 4H, 2 CH2), 1.99 (m, 2H, CH2), 2.34 (t, J = 7.2 Hz, 
2H, CH2), 3.49 (m, 2H, CH), 5.24 (m, 1H, CH), 6.95 (m, 2H, 2 aromat. CH), 7.25 (m, 1H, 
aromat. CH). 
13C-NMR (400 MHz, CDCl3): δ (ppm) = 23.3–34.0 (11 CH2), 73.6 (CH), 75.7 
(CH), 81.5 (CH), 123.1 (aromat. CH), 124.4  (aromat. CH), 126.8 (aromat. CH), 146.3 
(quart. C), 179.4 (CO). MS (EI): m/z (%) = 354 (M
+, 10), 336 (5), 326 (15), 168 (27), 126 
(100), 97 (65). HR-MS: C19H30O4S (354.51). HR-MS: Calcd.: 354.1865 Found: 354.1865. 
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